Cyclin-Dependent Kinase 7 (39 kDa Protein Kinase or CDK-Activating Kinase 1 or TFIIH Basal Transcription Factor Complex Kinase Subunit or EC 2.7.11.22) - Pipeline Review, H1 2016
Summary
Global Markets Directs, Cyclin-Dependent Kinase 7 (39 kDa Protein Kinase or CDK-Activating Kinase 1 or TFIIH Basal Transcription Factor Complex Kinase Subunit or EC 2.7.11.22) - Pipeline Review, H1 2016, provides in depth analysis on Cyclin-Dependent Kinase 7 (39 kDa Protein Kinase or CDK-Activating Kinase 1 or TFIIH Basal Transcription Factor Complex Kinase Subunit or EC 2.7.11.22) targeted pipeline therapeutics.
The report provides comprehensive information on the Cyclin-Dependent Kinase 7 (39 kDa Protein Kinase or CDK-Activating Kinase 1 or TFIIH Basal Transcription Factor Complex Kinase Subunit or EC 2.7.11.22), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Cyclin-Dependent Kinase 7 (39 kDa Protein Kinase or CDK-Activating Kinase 1 or TFIIH Basal Transcription Factor Complex Kinase Subunit or EC 2.7.11.22) targeted therapeutics development and features dormant and discontinued projects.
Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for Cyclin-Dependent Kinase 7 (39 kDa Protein Kinase or CDK-Activating Kinase 1 or TFIIH Basal Transcription Factor Complex Kinase Subunit or EC 2.7.11.22)
- The report reviews Cyclin-Dependent Kinase 7 (39 kDa Protein Kinase or CDK-Activating Kinase 1 or TFIIH Basal Transcription Factor Complex Kinase Subunit or EC 2.7.11.22) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Cyclin-Dependent Kinase 7 (39 kDa Protein Kinase or CDK-Activating Kinase 1 or TFIIH Basal Transcription Factor Complex Kinase Subunit or EC 2.7.11.22) targeted therapeutics and enlists all their major and minor projects
- The report assesses Cyclin-Dependent Kinase 7 (39 kDa Protein Kinase or CDK-Activating Kinase 1 or TFIIH Basal Transcription Factor Complex Kinase Subunit or EC 2.7.11.22) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Cyclin-Dependent Kinase 7 (39 kDa Protein Kinase or CDK-Activating Kinase 1 or TFIIH Basal Transcription Factor Complex Kinase Subunit or EC 2.7.11.22) targeted therapeutics
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Cyclin-Dependent Kinase 7 (39 kDa Protein Kinase or CDK-Activating Kinase 1 or TFIIH Basal Transcription Factor Complex Kinase Subunit or EC 2.7.11.22)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Cyclin-Dependent Kinase 7 (39 kDa Protein Kinase or CDK-Activating Kinase 1 or TFIIH Basal Transcription Factor Complex Kinase Subunit or EC 2.7.11.22) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
Table Of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Cyclin-Dependent Kinase 7 (39 kDa Protein Kinase or CDK-Activating Kinase 1 or TFIIH Basal Transcription Factor Complex Kinase Subunit or EC 2.7.11.22) Overview 7
Therapeutics Development 8
Cyclin-Dependent Kinase 7 (39 kDa Protein Kinase or CDK-Activating Kinase 1 or TFIIH Basal Transcription Factor Complex Kinase Subunit or EC 2.7.11.22) - Products under Development by Stage of Development 8
Cyclin-Dependent Kinase 7 (39 kDa Protein Kinase or CDK-Activating Kinase 1 or TFIIH Basal Transcription Factor Complex Kinase Subunit or EC 2.7.11.22) - Products under Development by Therapy Area 9
Cyclin-Dependent Kinase 7 (39 kDa Protein Kinase or CDK-Activating Kinase 1 or TFIIH Basal Transcription Factor Complex Kinase Subunit or EC 2.7.11.22) - Products under Development by Indication 10
Cyclin-Dependent Kinase 7 (39 kDa Protein Kinase or CDK-Activating Kinase 1 or TFIIH Basal Transcription Factor Complex Kinase Subunit or EC 2.7.11.22) - Pipeline Products Glance 12
Late Stage Products 12
Early Stage Products 13
Cyclin-Dependent Kinase 7 (39 kDa Protein Kinase or CDK-Activating Kinase 1 or TFIIH Basal Transcription Factor Complex Kinase Subunit or EC 2.7.11.22) - Products under Development by Companies 14
Cyclin-Dependent Kinase 7 (39 kDa Protein Kinase or CDK-Activating Kinase 1 or TFIIH Basal Transcription Factor Complex Kinase Subunit or EC 2.7.11.22) - Products under Development by Universities/Institutes 17
Cyclin-Dependent Kinase 7 (39 kDa Protein Kinase or CDK-Activating Kinase 1 or TFIIH Basal Transcription Factor Complex Kinase Subunit or EC 2.7.11.22) - Therapeutics Assessment 19
Assessment by Monotherapy/Combination Products 19
Assessment by Mechanism of Action 20
Assessment by Route of Administration 21
Assessment by Molecule Type 23
Cyclin-Dependent Kinase 7 (39 kDa Protein Kinase or CDK-Activating Kinase 1 or TFIIH Basal Transcription Factor Complex Kinase Subunit or EC 2.7.11.22) - Companies Involved in Therapeutics Development 24
Aurigene Discovery Technologies Limited 24
Beta Pharma, Inc. 25
Cyclacel Pharmaceuticals, Inc. 26
Syros Pharmaceuticals, Inc. 27
Tragara Pharmaceuticals, Inc. 28
Cyclin-Dependent Kinase 7 (39 kDa Protein Kinase or CDK-Activating Kinase 1 or TFIIH Basal Transcription Factor Complex Kinase Subunit or EC 2.7.11.22) - Drug Profiles 29
BS-181L - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
CYC-065 - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
sapacitabine + seliciclib - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
seliciclib - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
Small Molecule to Inhibit CDK7 for Oncology - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
Small Molecule to Inhibit CDK7 for Small Cell Lung Cancer - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
Small Molecules to Inhibit Cyclin-Dependent Kinase 7 for Oncology, Inflammation and Infectious Diseases - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
SY-1365 - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
SY-351 - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
TG-02 - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
Cyclin-Dependent Kinase 7 (39 kDa Protein Kinase or CDK-Activating Kinase 1 or TFIIH Basal Transcription Factor Complex Kinase Subunit or EC 2.7.11.22) - Dormant Projects 48
Cyclin-Dependent Kinase 7 (39 kDa Protein Kinase or CDK-Activating Kinase 1 or TFIIH Basal Transcription Factor Complex Kinase Subunit or EC 2.7.11.22) - Discontinued Products 49
Cyclin-Dependent Kinase 7 (39 kDa Protein Kinase or CDK-Activating Kinase 1 or TFIIH Basal Transcription Factor Complex Kinase Subunit or EC 2.7.11.22) - Featured News & Press Releases 50
Jun 10, 2016: Syros Pharmaceuticals Presents Data Demonstrating Significant Anti-Tumor Activity of its Lead Drug Candidate SY-1365 at 21st Congress of the European Hematology Association 50
Jun 06, 2016: Cyclacel Reports Updated Data From Its DNA Damage Response Program on Seliciclib and Sapacitabine Combination in Patients With Solid Tumors at ASCO 51
May 19, 2016: Cyclacels Seliciclib-Sapacitabine Abstract Selected for Oral Presentation at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting 52
May 19, 2016: Syros Pharmaceuticals to Present on SY-1365 at 21st Congress of the European Hematology Association 53
Apr 20, 2016: Syros Pharmaceuticals Presents New Data Demonstrating Significant Anti-Tumor Activity of its Selective CDK7 Inhibitor in Preclinical Models of Acute Myeloid Leukemia 53
Apr 18, 2016: Cyclacels Second-Generation CDK2/9 Inhibitor, CYC065, is an Effective Inducer of Cell Death in B-cell Lymphoma and Synergizes With Bcl-2 or BET Inhibitors 54
Apr 15, 2016: Aurigene to Present its CDK7 Covalent Inhibitor Program at AACR Annual Conference 55
Mar 16, 2016: Syros Pharmaceuticals to Present Preclinical Data on CDK7 Inhibitor Program in Blood Cancers at Upcoming AACR Annual Meeting 56
Dec 14, 2015: Molecular Basis for Development of Cyclacels CYC065 CDK2/9 Inhibitor in Triple-Negative Breast Cancer Presented at San Antonio Breast Cancer Symposium 57
Dec 05, 2015: Syros Pharmaceuticals Presents New Preclinical Data Demonstrating Significant Anti-Tumor Activity of First-in-Class Selective CDK7 Inhibitor in Models of Acute Leukemias 57
Nov 23, 2015: CYC065, Cyclacel's Novel CDK2/9 Inhibitor, Prolongs Survival in MYCN-Addicted Neuroblastoma Models 58
Nov 09, 2015: Mechanistic Rationale for CYC065, Cyclacel's CDK2/9 Inhibitor, in Targeted Solid Tumors and Hematological Malignancies Presented at AACR-NCI-EORTC International Conference 59
Nov 05, 2015: Syros Pharmaceuticals to Present Preclinical Data on First-in-Class Selective CDK7 Inhibitor Program at American Society of Hematology Annual Meeting 60
Oct 26, 2015: Data to be Presented on CYC065, Cyclacel's CDK2/9 Inhibitor, at AACR-NCI-EORTC International Conference 60
Oct 22, 2015: Cyclacel Doses First Patient in Phase 1 Trial of Its Novel CDK2/9 Inhibitor, CYC065, for the Treatment of Advanced Solid Tumors 61
Appendix 62
Methodology 62
Coverage 62
Secondary Research 62
Primary Research 62
Expert Panel Validation 62
Contact Us 62
Disclaimer 63
List Of Tables
Number of Products under Development for, H1 2016 8
Number of Products under Development by Therapy Area, H1 2016 9
Number of Products under Development by Indication, H1 2016 10
Comparative Analysis by Late Stage Development, H1 2016 12
Comparative Analysis by Early Stage Products, H1 2016 13
Number of Products under Development by Companies, H1 2016 14
Products under Development by Companies, H1 2016 15
Products under Development by Companies, H1 2016 (Contd..1) 16
Number of Products under Investigation by Universities/Institutes, H1 2016 17
Products under Investigation by Universities/Institutes, H1 2016 18
Assessment by Monotherapy/Combination Products, H1 2016 19
Number of Products by Stage and Mechanism of Action, H1 2016 20
Number of Products by Stage and Route of Administration, H1 2016 22
Number of Products by Stage and Molecule Type, H1 2016 23
Pipeline by Aurigene Discovery Technologies Limited, H1 2016 24
Pipeline by Beta Pharma, Inc., H1 2016 25
Pipeline by Cyclacel Pharmaceuticals, Inc., H1 2016 26
Pipeline by Syros Pharmaceuticals, Inc., H1 2016 27
Pipeline by Tragara Pharmaceuticals, Inc., H1 2016 28
Dormant Projects, H1 2016 48
Discontinued Products, H1 2016 49
List Of Figures
Number of Products under Development for, H1 2016 8
Number of Products under Development by Therapy Area, H1 2016 9
Number of Products under Development by Top 10 Indication, H1 2016 10
Comparative Analysis by Early Stage Products, H1 2016 13
Assessment by Monotherapy/Combination Products, H1 2016 19
Number of Products by Stage and Mechanism of Actions, H1 2016 20
Number of Products by Routes of Administration, H1 2016 21
Number of Products by Stage and Routes of Administration, H1 2016 21
Number of Products by Stage and Molecule Type, H1 2016 23
